For reasons no one has yet explained, a provision in the new health care reform law removes a previously Congressionally-mandated discount to children’s hospitals for drugs used to treat so-called “orphan diseases,” illnesses that are not common enough for the drugs to be profitable. Pharmaceutical companies have begun notifying the hospitals that they no longer qualify for the discounts, and the change will cost  hundreds of millions of dollars, as well as put sick kids at risk. Continue reading →